Lv11
40 积分 2025-12-08 加入
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
3小时前
待确认
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
1个月前
已完结
Therapeutic targeting of tumour myeloid cells
1个月前
已完结
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
1个月前
已完结
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy
2个月前
已完结
Targeting B Cells and Plasma Cells in Glomerular Disease
2个月前
已完结
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
2个月前
已完结
皖公网安备34019202002308
